NAV financing is borrowing supported principally by the value and expected cash flows of a fund’s existing investment portfolio. It can provide liquidity after much of the fund’s committed capital has been invested, helping finance follow-on investments or other permitted purposes. Unlike a subscription facility, its central underwriting reference is the portfolio rather than primarily the credit quality of investors with uncalled commitments. The structure can avoid an immediate asset sale, but it introduces leverage and claims on future proceeds. Its suitability depends on what can be realised, when distributions are likely to arrive and how investor interests are protected. This article considers NAV financing for private equity and venture capital funds as at 27 April 2026, without treating reported net asset value as equivalent to cash or collateral value.

A fund’s financing needs change as it invests. Early in its life, a subscription facility may bridge investor capital calls. Later, remaining uncalled capital can decline while the portfolio still requires follow-on funding or time to realise value. NAV financing addresses that later-stage liquidity need by looking to the investments already held and the proceeds they may generate. The borrowing entity may be the fund or a dedicated holding structure, depending on legal, tax and commercial considerations. The lender’s claim can be supported by pledges over holding-company interests, distribution rights and collection accounts. The exact package matters because portfolio-company debt and investment restrictions can limit access to underlying assets or cash. A facility can fund value-enhancing activity, such as an acquisition within the portfolio, or provide distributions to investors. These uses have different economic implications. Borrowing for an investment may generate additional returns if the investment performs. Borrowing for a distribution accelerates liquidity but does not itself create operating value. The financing cost remains payable in either case. The key distinction is between liquidity and solvency. A portfolio may contain valuable assets that cannot be sold quickly without a discount. Debt can address timing, but it cannot establish that the underlying valuations are sound. Lenders and investors should examine both the use of proceeds and the evidence that future realisations can cover the obligation.

NAV finance has attracted dedicated institutional capital. In July 2025, 17Capital announced approximately US$5.5 billion of commitments for Strategic Lending Fund 6, including co-investment and affiliated vehicles. This is evidence of capital raised for a strategy, not an estimate of total market size or the amount subsequently lent to funds. Commitments and deployment should remain separate in any market assessment. Investor governance has developed alongside that capital formation. ILPA published NAV-based facilities guidance in July 2024, focusing on transparency and dialogue between managers and limited partners. Its recommendations include seeking LPAC consent where the limited partnership agreement is silent and particular engagement around facilities used for distributions. These are industry recommendations, not a substitute for the governing agreement or applicable law. The distinction matters because fund documents were not all drafted with the same financing structures in mind. A general borrowing permission may not answer every question about a new subsidiary or a claim on portfolio distributions. Managers should examine the substance of the proposed leverage rather than rely only on the legal location of the borrower. For investors, the central concern is how the facility changes risk and reported performance. Earlier cash distributions can improve timing-based metrics while adding interest expense and reducing later proceeds. Clear reporting should make that effect understandable without presenting financed liquidity as the same achievement as an asset realisation.

A lender normally applies its own eligibility and valuation framework to the portfolio. Reported NAV is an input, not necessarily the borrowing base. Concentrated positions, difficult transfer rights, uncertain valuations or limited distribution visibility can attract haircuts or exclusion. The result can be materially lower than the value shown in investor reporting. Loan-to-value compares the relevant debt balance with the defined collateral value. Consider an illustrative portfolio reported at €100 million. If the lender recognises €80 million after adjustments and advances €16 million, the initial ratio is 20% of eligible value, although it is only 16% of reported NAV. Those percentages describe different denominators and should not be used interchangeably. If eligible value falls to €64 million while debt remains €16 million, the ratio rises to 25%. Whether that creates a breach depends on the agreement. The documents may require repayment, additional collateral, a cash sweep or other action. A fund can therefore experience financing pressure without a realised investment loss or an immediate asset sale. Security and collection mechanics determine how the lender accesses proceeds. Cash may flow through controlled accounts and be applied to interest and principal before investor distributions. Transfer restrictions, existing portfolio-company debt and enforcement considerations need to be addressed. A pledge over a holding structure does not automatically give the lender unrestricted direct control of every underlying company.

A mature private-equity portfolio may contain businesses with operating cash flow, observable earnings and identifiable exit routes. Even then, underlying company leverage can limit distributions, and several holdings may be exposed to the same economic cycle. Diversification by company name is not the same as diversification by risk. A lender should examine correlated demand, geography and financing conditions. A venture portfolio can be more difficult to underwrite. Value may depend on future financing rounds or a small number of potential exits, while many companies remain cash-consuming. A recent equity round provides a valuation reference but does not guarantee a sale at that price. Preference rights and dilution can also change the value attributable to the fund’s specific share class. The underwriting response should reflect those differences. Concentration limits, more conservative valuation assumptions or lower advance rates may be appropriate, but no universal ratio applies to every VC portfolio. A later-stage venture fund with visible liquidity events can differ materially from a seed fund with long-duration binary outcomes. The fund’s own follow-on obligations matter as well. Borrowing may provide capital to protect valuable holdings, yet a weak market can increase investment needs while delaying exits. The debt model should capture that combination. A facility sized only against current NAV can overstate resilience if the portfolio will require substantial additional capital before it can produce distributable proceeds.

The financing cost includes interest, arrangement expenses and any other agreed return components. Cash-pay interest requires an interim servicing source, while capitalised interest increases the amount due later. A distribution sweep can reduce refinancing risk but restrict the cash investors receive. The economic assessment should model the net proceeds available to limited partners after the facility is repaid. Specialist private-credit platforms and banks participate in fund finance, but a manager should not assume that a lender active in subscription lines will also underwrite portfolio risk. The relevant experience concerns valuation, concentration and enforcement across the proposed asset mix. A provider focused on large buyout sponsors may not fit a smaller VC fund even if both use the term NAV financing. Alternatives include asset sales, secondary transactions, additional investor capital where permitted, or preferred capital structures. Each changes the allocation of risk and return. Selling an asset produces liquidity without loan maturity but can crystallise a discount. Preferred capital may provide a different distribution priority, although its effective cost and control rights still need careful modelling. The comparison should use the same portfolio assumptions. A loan may be attractive if it avoids selling a strong asset before a credible value event. It is less convincing if it merely postpones recognition of a weak investment. The decision should identify the incremental value expected from waiting and compare it with financing cost and the risk of a forced sale later.

Before committing, the manager should establish its authority under the fund agreement and any relevant side letters. The analysis should cover the purpose of borrowing, limits, security and investor consultation. LPAC engagement can help address conflicts, but the precise approval process depends on the documents. Industry guidance does not itself amend contractual rights. Reporting should distinguish asset-sale proceeds from debt-funded distributions and explain the remaining liability. Investors need to understand the facility’s purpose, maturity, cost and material constraints. Valuation changes and loan-to-value calculations should use consistent definitions. A higher distribution-to-paid-in ratio funded through borrowing should not obscure the corresponding claim on future proceeds. Stress testing should combine valuation reductions with delayed exits and additional portfolio support. The manager should identify when distributions become trapped, whether covenant cures are feasible and which assets could be sold without damaging the remaining portfolio. Reliance on a single imminent exit can create concentration in repayment even where the fund holds many investments. An exit from the facility should be planned at inception. Loan maturity, fund term and realistic disposal timing need to align, with contingency for extensions that are not guaranteed. The manager should also consider how the facility affects a future continuation transaction or fund restructuring. NAV finance should increase the fund’s ability to manage timing, not create a new deadline that forces decisions against investor interests.

NAV financing converts part of a portfolio’s expected future liquidity into cash available today. That can support valuable follow-on activity or avoid an untimely disposal, but it also places a senior claim on later proceeds. The decision depends on eligible collateral value, distribution timing and the purpose for which the borrowed money will be used. For PE and VC funds, the same instrument name can conceal very different underwriting risks. A sound structure combines conservative valuation, realistic repayment and transparent investor governance. It should be judged by its effect on net investor outcomes under stress, rather than the immediate increase in liquidity or the appearance of improved distribution metrics.

A subscription facility principally relies on investors’ uncalled commitments and associated capital-call rights. NAV financing principally relies on existing portfolio value and distributions. Hybrid structures can combine both. The distinction affects diligence, collateral, covenant design and where the lender expects repayment to come from.

It may be possible, but a portfolio with uncertain valuations, concentrated outcomes and limited near-term distributions can support little conventional debt capacity. The lender must evaluate the specific assets and repayment path. A high reported NAV alone does not establish that a facility is available or appropriate.

It accelerates cash received by investors and may improve timing-sensitive metrics, but it does not itself create investment profit. Interest and other costs reduce later proceeds unless offset by benefits elsewhere. Reporting should distinguish financed distributions from realisations so investors can evaluate the underlying economic outcome.